Savant Capital’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$47.9M Buy
52,081
+3,887
+8% +$3.94M 0.23% 65
2025
Q4
$51.8M Sell
48,194
-516
-1% -$493K 0.29% 55
2025
Q3
$37.2M Buy
48,710
+694
+1% +$516K 0.23% 71
2025
Q2
$37.4M Buy
48,016
+2,326
+5% +$1.81M 0.27% 59
2025
Q1
$37.7M Sell
45,690
-4,040
-8% -$3.36M 0.32% 49
2024
Q4
$38.4M Sell
49,730
-3,270
-6% -$2.71M 0.3% 56
2024
Q3
$47M Buy
53,000
+11,503
+28% +$10.3M 0.39% 46
2024
Q2
$37.6M Sell
41,497
-1,454
-3% -$1.16M 0.38% 53
2024
Q1
$33.4M Buy
42,951
+1,301
+3% +$926K 0.38% 53
2023
Q4
$24.3M Sell
41,650
-954
-2% -$557K 0.31% 58
2023
Q3
$22.9M Sell
42,604
-992
-2% -$511K 0.34% 52
2023
Q2
$20.4M Buy
43,596
+3,082
+8% +$1.29M 0.32% 58
2023
Q1
$13.9M Buy
40,514
+4,423
+12% +$1.49M 0.26% 70
2022
Q4
$13.1M Buy
36,091
+960
+3% +$340K 0.32% 48
2022
Q3
$11.4M Buy
35,131
+580
+2% +$184K 0.35% 46
2022
Q2
$11.2M Buy
34,551
+844
+3% +$253K 0.34% 46
2022
Q1
$9.65M Buy
33,707
+2,063
+7% +$531K 0.32% 53
2021
Q4
$8.74M Buy
31,644
+323
+1% +$81.9K 0.28% 57
2021
Q3
$7.24M Buy
31,321
+19,435
+164% +$4.8M 0.26% 56
2021
Q2
$2.73M Sell
11,886
-328
-3% -$65.9K 0.11% 103
2021
Q1
$2.28M Buy
12,214
+119
+1% +$23.3K 0.12% 110
2020
Q4
$2.04M Buy
12,095
+649
+6% +$96.9K 0.12% 114
2020
Q3
$1.69M Buy
11,446
+127
+1% +$19.7K 0.12% 124
2020
Q2
$1.86M Buy
11,319
+826
+8% +$127K 0.14% 117
2020
Q1
$1.46M Buy
10,493
+1,056
+11% +$145K 0.14% 123
2019
Q4
$1.24M Sell
9,437
-7
-0.1% -$811 0.15% 116
2019
Q3
$1.06M Sell
9,444
-107
-1% -$11.9K 0.15% 116
2019
Q2
$1.06M Sell
9,551
-542
-5% -$63.8K 0.15% 116
2019
Q1
$1.31M Buy
10,093
+73
+0.7% +$8.88K 0.25% 80
2018
Q4
$1.16M Buy
10,020
+2,303
+30% +$257K 0.24% 81
2018
Q3
$828K Buy
7,717
+143
+2% +$14.3K 0.15% 117
2018
Q2
$646K Sell
7,574
-60
-0.8% -$4.93K 0.14% 121
2018
Q1
$591K Buy
7,634
+50
+0.7% +$4.03K 0.12% 131
2017
Q4
$641K Buy
7,584
+246
+3% +$20.9K 0.13% 121
2017
Q3
$628K Buy
7,338
+30
+0.4% +$2.46K 0.14% 113
2017
Q2
$601K Sell
7,308
-217
-3% -$17.7K 0.14% 115
2017
Q1
$633K Buy
7,525
+736
+11% +$59K 0.16% 106
2016
Q4
$499K Sell
6,789
-10
-0.1% -$745 0.13% 126
2016
Q3
$546K Sell
6,799
-390
-5% -$31.2K 0.15% 113
2016
Q2
$566K Buy
7,189
+100
+1% +$7.53K 0.16% 110
2016
Q1
$510K Sell
7,089
-628
-8% -$47.5K 0.15% 110
2015
Q4
$650K Buy
7,717
+1,830
+31% +$152K 0.2% 80
2015
Q3
$493K Buy
5,887
+2,007
+52% +$169K 0.18% 97
2015
Q2
$324K Buy
3,880
+100
+3% +$7.62K 0.11% 151
2015
Q1
$275K Buy
3,780
+40
+1% +$2.85K 0.1% 170
2014
Q4
$258K Buy
3,740
+184
+5% +$12.4K 0.1% 177
2014
Q3
$231K Sell
3,556
-74
-2% -$4.68K 0.1% 177
2014
Q2
$226K Buy
3,630
+90
+3% +$5.37K 0.1% 172
2014
Q1
$208K Buy
+3,540
New +$198K 0.1% 173

Other funds holding LLY

Savant Capital's LLY Position: Q1 2026 in Review

Savant Capital increased its Eli Lilly (LLY) stake by 8.1% in Q1 2026, buying an estimated $3.94M and bringing the position to 52,081 shares worth $47.9M. The position accounts for 0.23% of the portfolio, ranked #65.

Savant Capital first reported a position in LLY in Q1 2014 and has held it in 49 quarters since. The position peaked at $51.8M in Q4 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Savant Capital held 52,081 shares of Eli Lilly worth $47.9M as of Q1 2026.
  • Savant Capital bought 3,887 Eli Lilly shares in Q1 2026, an estimated $3.94M.
  • Eli Lilly made up 0.23% of Savant Capital's portfolio in Q1 2026, its #65 holding.
  • Savant Capital first reported a position in Eli Lilly in Q1 2014 and has held it in 49 quarters since.
  • Savant Capital's Eli Lilly position peaked at $51.8M in Q4 2025.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Savant Capital's 13F filing for Q1 2026, filed 4 May 2026.